Research programme: immune disorder therapeutics - Alumis
Latest Information Update: 12 Jan 2022
At a glance
- Originator Esker Therapeutics
- Developer Alumis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 06 Jan 2022 Esker Therapeutics is now called Alumis
- 31 Aug 2021 Early research in Autoimmune disorders in USA (unspecified route), prior to August 2021 (Esker Therapeutics pipeline, August 2021)